News

Collaboration Enables Use of Actionable, Patient-Generated Data in Clinical Trials from Extensive Range of mHealth Sensors, Wearables and Apps

Collaboration Enables Use of Actionable, Patient-Generated Data in Clinical Trials from Extensive Range of mHealth Sensors, Wearables and Apps

Quorum Review IRB is introducing a comprehensive program that supports the needs of Phase I Healthy patients.

With the Perceptive MyTrials Analytics solution, clinical trial sponsors can now use a mobile-enabled, single entry-point to access predictive data analytics.

To mark the 50th anniversary of the adoption of the first European Union (EU) pharmaceutical legislation, the European Commission is organizing a one-day conference that will take place in Brussels September 28.

..

Wingspan Technology now offers an eTMF Readiness Assessment program to help sponsors and CROs assess their level of readiness for implementing eTMF.

According to the release, PPD noted that wearable technology will have the potential to benefit Novartis and its other clients because of the integration with the technologies patients use on a daily basis.

The aforementioned article emphasized that a reduction in data quality ultimately leads to enrolling more clinical trial subjects in order to maintain equivalent statistical power.

The program is designed to facilitate dialogue between industry stakeholders and clinical research sites.

In light of two recent announcements, and this excellent article from Bloomberg it appears the role of social media in post-market adverse event reporting is being taken seriously by the FDA.

The need for more efficient clinical trials is driving greater use of cloud-based solutions, especially with the rise in globalization

Designed to ensure patients and patients in clinical trials safely receive their proper medications, the regulation serves as a verification measure to enforce the European Union’s Falsified Medicine Directive.

In this analysis, distinctions between who hires who in non-Chinese and China-based companies emerges.

The new Clinical Conductor contains a myriad of enhancements that foster more precise reporting and analysis.

July 14, 2015 – ROCHESTER, NY – The latest iteration of Clinical Conductor CTMS continues the proven strategy of providing research organizations with the most in-depth features and functionality available, further distancing the application from others in the industry, which fail to provide the tools necessary for truly complete clinical research management.

Adopting scientific quality measurement that recognizes that clinical trials are a service will reap benefits.

EDC has become the data management platform of choice around the world, offering advantages such as increasing the quality and timely collection of data. Medrio, an EDC company that offers eClinical software solutions, has quoted that 70% of clinical trials are using EDC as a forms of collecting data in the United States. In China, we have seen adoption rates for EDC increase dramatically in recent years, fuelled by improved technology developments in mobile applications, and the increasing experience with EDC usage in clinical research.

Considerable quality investments over the past decade have had little demonstrable impact on clinical trial performance and quality.

The use of small animal models in basic and preclinical research is now an integral part of developing and testing new drugs.

 It is well known within the industry that being on a sponsor’s preferred provider list affords a critical leg up to providers hoping to win business. Phase II/III work is no exception. In the 7th edition of Industry Standard Research’s CRO Quality Benchmarking - Phase II/III Service Providers report, ISR digs a bit deeper into the dynamics of preferred provider lists and how these lists affect CRO selection for Phase II/III studies.